

Posters

- * **P 012 A RANDOMIZED INVESTIGATOR-BLINDED COMPARATIVE STUDY OF CALCITRIOL TWICE A DAY VS. DIFLUCORTOLONE VALERATE MORNING PLUS CALCITRIOL EVENING APPLICATION IN THE TREATMENT OF MILD TO MODERATE PSORIASIS**
J. Lee, J. Youn, N. Kim, K. Kim, T. Kim, J. Choi, W. Lew, Y. Choe (South Korea)
- * **P 021 HIGH DOSE EXCIMER PHOTOTHERAPY FOR LOCALIZED PSORIASIS**
S. Dahan, G. Toubel (France)
- P 038 ASSESSMENT OF PATIENTS' PSORIASIS SEVERITY BY RELATIVES AND PARTNERS**
A. M. Eghlileb, A. Y. Finlay (United Kingdom)
- P 039 PASI 100 IS ASSOCIATED WITH BETTER DERMATOLOGY-SPECIFIC PATIENT-REPORTED OUTCOMES VS. PASI 75**C99 IN ADALIMUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS: SUBANALYSIS OF THE ADEPT TRIAL**
D. D. Gladman, P. J. Mease, C. T. Ritchlin, M. O. Okun (Canada)
- P 040 THE CLINICAL USEFULNESS OF THE JAPANESE VERSION OF THE PSORIASIS DISABILITY INDEX IN PATIENTS WITH PSORIASIS.**
O. Fukuchi, T. Ito, T. Hasegawa, H. Nakagawa (Japan)
- P 041 INTRALESIONAL MRNA IL-10 EXPRESSION IN PSORIASIS: CORRELATION BETWEEN MRNA LEVEL AND DISEASE SEVERITY**
Y. Galai, S. Samoud, N. Kenani, M. Denguezli, N. Zinelabidine, R. Nouira, H. Louzir (Tunisia)
- P 042 THE ARABIC VERSION OF THE DERMATOLOGY LIFE QUALITY INDEX FOR MOROCCO: A STUDY OF RELIABILITY AND VALIDITY IN PSORIATICS**
I. Khoudri, M. Rmili, N. Ismaili, B. Hassam, A. Zeggwagh, R. Abouqal (Morocco)
- P 043 NEUTROPHIL ACTIVATION ASSOCIATED TO PSORIASIS VULGARIS SEVERITY**
S. Coimbra, E. Castro, P. Rocha-Pereira, H. Oliveira, L. Belo, F. Reis, S. Rocha, A. Figueiredo, F. Teixeira, A. Santos-Silva (Portugal)
- P 044 METHODS FOR ASSESSING EFFICACY OF PSORIASIS THERAPIES**
C. N. Ellis, J. Berth-Jones (USA)
- P 045 IMPACT OF PSORIASIS ON QUALITY OF LIFE IN IRAN**
S. Aghaei, G. Safaee Ardekani (Islamic Republic of Iran)
- P 046 QUALITY OF LIFE AND PSORIASIS: THEMATIC ANALYSIS OF 50 EXPLORATORY INTERVIEWS AND CONSTRUCTION OF A FRENCH QUESTIONNAIRE, THE "QUALIPSO"**
B. Quintard, A. Coelier, E. Leconte, Y. Guiguen, A. Taieb (France)
- P 047 QUALITY OF LIFE IN PATIENTS WITH CHRONIC PSORIASIS**
A. Nemcova, D. Kovandova, J. Hercogova, R. Schmiedbergerova (Czech Republic)
- P 048 INEFFECTIVENESS OF DAPSONE IN THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS: REPORT OF 2 CASES**
H. Hammami, K. Jaber, S. Youssef, M. Dhaoui, N. Doss (Tunisia)
- P 049 GENERALIZED PUSTULAR PSORIASIS (GPP) AT DAKAR**
L. Fatimata, M. M. T. Dieng, F. F. S. Sarr, O. O. S. N. Niang, A. A. S. Kane, B. B. N. Ndiaye (Senegal)
- P 050 THERAPEUTIC METHODS OF SEVERE PSORIASIS (35 CASES)**
H. El Jed, M. Mseddi, A. Damak, A. Masmoudi, S. Boudaya, H. Turki (Tunisia)
- P 051 REASONS FOR HOSPITALIZATION OF PERSONS WITH PSORIASIS**
H. El Jed, M. Mseddi, T. Meziou, S. Boudaya, H. Turki (Tunisia)
- P 052 PSORIASIS THERAPY POSSIBILITIES IN CHILDREN**
H. Zelenkova, J. Stracenska (Slovakia)
- P 053 EFFECTIVE TREATMENT OF PSORIASIS WITH METHOTREXATE: A CASE REPORT**
V. Dragos, T. Avcin (Slovenia)
- P 054 FAMILIAL JUVENILE PUSTULAR PSORIASIS**
H. El Jed, M. Mseddi, T. Meziou, S. Boudaya, H. Turki (Tunisia)
- P 055 SUCCESSFUL TREATMENT OF RECALCITRANT PALMOPLANTAR PUSTULAR PSORIASIS WITH INFILIXIMAB**
N. Yawalkar (Switzerland)
- P 056 PSORIASIS PALMOPLANTAIR KÉRATODERMIA**
E. Nadia, H. Mirrane, I. Taddaoui, T. Marcil, L. Benzekri, K. Senouci, B. Hassam (Morocco)
- P 057 TOPICAL PSORIASIS THERAPY – ALTERNATIVE THERAPY NEWS**
H. Zelenkova, J. Stracenska (Slovakia)
- P 058 SWITCH FROM COMBINATION THERAPY OF TOPICAL ACTIVE VITAMIN D3 AND STEROID TO MONO THERAPY OF TOPICAL ACTIVE VITAMIN D3 IN PLAQUE-TYPE PSORIASIS**
T. Ito, O. Fukuchi, H. Nakagawa (Japan)

- P 059 MONITORING THE EVOLUTION OF PSORIASIS CLINICAL SIGNS AND SYMPTOMS UNDER TOPICAL TREATMENT WITH CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE COMBINATION OINTMENT**
R. Olsavszki, C. Sabau, C. Belmega (Romania)
- P 060 EFFECT OF NAPHTHALENE THERAPY ON PROLIFERATION ACTIVITY, IMMUNOREACTIVITY AND ANGIOGENESIS IN THE SKIN OF PSORIASIS PATIENTS**
G. Krnjevic Pezic, J. Razumovic-Jakic, P. Vrzogic, J. Lipozencic, A. Pasic, A. Smeh-Skrbin (Croatia)
- P 061 EPIDEMIOLOGY OF PSORIASIS: EXPERIENCE IN ALGERIA DURING 25 YEARS**
B. B. S. O. Omar, B. D. B. Dahmani, A. B. A. Belbachir (Algeria)
- P 062 PSORIASIS: EPIDEMIOLOGY, CLINICAL DATA AND CURRENT MANAGEMENT: A RETROSPECTIVE ANALYSIS OF 405 PATIENTS**
H. Hammani, S. Youssef, K. Jaber, M. Dhaoui, N. Doss (Tunisia)
- P 063 A CLINICAL SURVEY OF PSORIASIS IN GEORGIA**
N. Lortkipanidze, M. Tevzadze, N. Nogaideli (Georgia)
- P 064 EPIDEMIOLOGY OF PSORIASIS IN TUNISIA**
N. El Fekih, A. Khaled, M. Kharfi, A. Sellami, F. Zeglaoui, B. Fazaa, S. Gaigi, M. Kamoun (Tunisia)
- P 065 THE PROFILE OF PUSTULAR PSORIASIS: A REPORT OF 34 CASES**
A. Dammak, T. Meziou, N. Krid, W. Abdelmaksouda, M. Mseddi, S. Boudaya, H. Turki (Tunisia)
- P 066 A SUPPORT PROGRAM FOR PSORIASIS FRIENDS OF THE SKIN PROJECT AT UNIVERSITY HOSPITAL IN BRAZILIA (HUB) BRAZIL**
G. A. Martins, N. N. M. Almeida, H. H. F. Tajra (Brazil)
- P 067 PSORIASIS: 5 YEAR EXPERIENCE**
Z. Topkarci, G. Ozarmagan (Turkey)
- P 068 PSORIASIS: AN EPIDEMIOLOGIC STUDY OF 2987 CASES**
S. Skali, R. Berrada, B. Benani, M. El Alaoui, H. Benchikhi, H. Lakhdar (Morocco)
- P 069 A COMPARISON OF THE PHARMACOKINETICS REGARDING PREPRANDIAL AND POSTPRANDIAL ADMINISTRATION OF CYCLOSPORINE IN PATIENTS WITH PSORIASIS**
Y. Umezawa, E. Akasaka, S. Tamiya, T. Mabuchi, T. Matsuyama, A. Ozawa (Japan)
- P 070 SUCCESSFUL TREATMENT OF PSORIATIC NAILS WITH LOW-DOSE CYCLOSPORIN ADMINISTRATION**
M. Abe, T. Syuto, H. Ishibuchi, O. Ishikawa (Japan)
- P 071 EVALUATION OF THE RESPONSE TO PHOTOTHERAPY AT DIFFERENT BODY SITES IN CHRONIC PLAQUE-TYPE PSORIASIS**
M. Ghiasi (Islamic Republic of Iran)
- P 072 PRE-TREATMENT OF SUPERFICIAL ABLATION DURING 308 NM EXCIMER LASER THERAPY IN PATIENTS WITH CHRONIC RECALCITRANT PSORIATIC PLAQUES**
D. Kim, Y. Park (South Korea)
- P 073 EXPERIENCE OF BALNEOPHOTOTHERAPY FOR PSORIASIS WITH THE USE OF RESOURCES OF THE KUNIGUNDA SALT LAKE IN THE TRANSCARPATHEAN REGION (UKRAINE)**
Y. V. Andrashko, H. E. Astsaturov (Ukraine)
- P 074 CLIMATOTHERAPY AT THE DEAD SEA IN JORDAN-A REAL ALTERNATIVE IN TREATING PSORIASIS**
Z. Z. Bisharat (Jordan)
- P 075 SHORT CONTACT ICHTHYOL AND NARROW BAND UVB: AN OLD-NEW COMBINATION THERAPY**
N. Benáková (Czech Republic)
- P 076 TAMOXIFEN AND PSORIASIS**
S. Benomar, S. Boutayeb, N. Ismaili, B. Hassam (Morocco)
- P 077 PASI AND LIFE STYLE FACTORS IN PSORIASIS PATIENTS ADMITTED TO CLIMATE THERAPY**
E. Fjelde, A. Hareide, L. Salo, M. Massanet, J. Bach, A. Krogstad (Spain)
- P 078 TREATMENT OF PSORIASIS WITH BIOFEEDBACK THERAPEUTICS: A SUMMARY REPORT OF 15 YEARS**
X.Q. Yang, I. Zhang, L. Zhang, J. Cheng (China)
- P 079 EFFICACY STUDY OF OPTODERMA® « CELLULAR MEMORIZER » ON SUBJECTS WITH PSORIASIS SYMPTOMS DUE TO PSORIASIS VULGARIS**
A. Deák, F. Attila (Belgium)
- P 080 EFFECTS OF ANTI-TNF-ALPHA TREATMENTS ON BODY WEIGHT IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS: A RETROSPECTIVE COHORT STUDY**
P. Gisondi, C. Cotena, G. Girolomoni (Italy)
- P 081 FACTORS INFLUENCING THE OUTCOME OF THE TREATMENT WITH EFALIZUMAB FOR PSORIASIS**
C. Solovan, M. Ciolan (Romania)
- P 082 ETANERCEPT TREATMENT IN PSORIASIS- SINGLE CENTER OBSERVATIONAL STUDY ON DIFFERENT THERAPY REGIMENS**
E. Bulbul Baskan, M. Yilmaz, S. Toker, S. Tunalı (Turkey)

- P 083 INITIAL EXPERINECE WITH ROUTINE ADMINISTRATION OF ETANERCEPT IN PSORIASIS**
M. de Groot, M. Appelman, P. I. Spuls, M. A. de Rie, J. D. Bos (The Netherlands)
- P 084 ADALIMUMAB FOR THE TREATMENT OF 6 PATIENTS WITH SEVERE PSORIASIS**
D. Vidal, H. Corominas, J. Smandia, R. Figuls, M. Cerdán, M. Riera, A. Ravella (Spain)
- P 085 PSORIASIS INDUCED BY ANTI-TUMOR NECROSIS FACTOR THERAPY: REPORT OF THREE CASES**
C. Muñoz-Santos, M. Moreno, N. Fernandez-Chico, J. Luelmo (Spain)
- P 086 A STUDY OF 56 TUNISIAN PSORIATIC PATIENTS BEFORE TREATMENT: HIGH INCIDENCE OF ANTI-NUCLEAR ANTIBODIES AND INSIGNIFICANT PRESENCE OF ANTI-CCP, ANCA, AND RHEUMATOID FACTORS**
S. Samoud, Y. Galai, N. Kenani, R. Ben Asker, H. Kebaiier, M. Ben Ahmed, M. Denguezli, H. Louzir (Tunisia)
- P 087 ADALIMUMAB (HUMIRA®) IMPROVES NAIL PSORIASIS IN PSA: RESULTS FROM LARGE, OPEN-LABEL STUDY (STEREO)**
F. Van den Bosch, R. Reece, F. Behrens, D. Wendling, K. Mikkelsen, M. Frank, M. Kron, H. Kuppere (Belgium)
- P 088 RESULTS OF A PHASE II STUDY OF CNTO 1275 IN THE TREATMENT OF PSORIASIS**
G. G. Krueger, R. Langley, C. Leonardi, N. Yeilding, C. Guzzo, Y. Wang, C. Brodmerkel, M. Leibold (USA)
- P 089 DEVELOPMENT OF ANTIBODIES TO INFLIXIMAB AND RELATIONSHIP WITH THE LONG-TERM EFFICACY IN PATIENTS WITH PSORIASIS**
O. Baniandrés, M. T. Gárate, M. Fernández-Guarino, S. Aboín, P. Jaén (Spain)
- P 090 EFFICACY AND SAFETY OF ETANERCEPT IN MODERATE TO SEVERE PLAQUE PSORIASIS**
M. Tunca, E. Koc, A. Akar, Z. Kurumlu (Turkey)
- P 091 CLINICAL TREATMENT OF PSORIASIS VULGARIS AND PSORIATIS ARTHRITIS WITH ETANERCEPT - OUR EXPERIENCES**
J. Jautova, J. Baloghova, Z. Macejova (Slovakia)
- P 092 THE PSORIASIS VULGARIS WITH EFALIZUMAB - OUR EXPERIENCES**
J. Jautova, T. Kampe, J. Baloghova, M. Ficova (Slovakia)
- P 093 COST EFFECTIVENESS OF BIOLOGICS FOR MODERATE TO SEVERE PSORIASIS FROM THE PERSPECTIVE OF THE SWISS HEALTHCARE SYSTEM**
R. Greiner, L. R. Braathen (Germany)
- P 094 MULTIPLE WIDESPREAD VERRUCAE DUE TO ETANERCEPT TREATMENT IN A PSORIATIC PATIENT**
E. Koc, M. Tunca, A. Akar, Z. Kurumlu (Turkey)
- P 095 TREATMENT OF PSORIASIS BY EFALUZIMAB. A REPORT ON TEN CASES**
J. Unanue (France)
- P 096 ADALIMUMAB IN PSORIASIS. OUR EXPERIENCE**
T. Sanz- Sanchez, E. E. Dauden, J. J. Pedraz, A. A. García-Diez (Spain)
- P 097 INFLIXIMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS. CURRENT DAILY PRACTICE**
T. Sanz- Sanchez, E. E. Daudén, R. R. Goiriz, A. A. García-Diez (Spain)
- P 098 ADALIMUMAB FOR SEVERE PSORIASIS AND PSORIATIC ARTHRITIS: AN OPEN LABEL STUDY IN 30 PATIENTS PREVIOUSLY TREATED WITH OTHER BIOLOGICS**
M. Papoutsaki, M. S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, A. Giunta, L. Bianchi, S. Chimenti (Italy)
- P 099 PSORIASIS AND BIOLOGICAL THERAPY: USE OF QUANTIFERON® TB-GOLD (QFT-G), AND T-SPOT® TB TO INVESTIGATE TUBERCULOSIS**
N. Balato, F. Ayala, G. Cimmino, F. Gaudiello, B. Bellofiore, A. Sanduzzi (Italy)
- P 100 USE OF ETANERCEPT IN PATIENTS WITH PSORIASIS AND CONCOMITANT HEPATITIS C INFECTION**
A. Mazzotta, M. Esposito, C. Casciello, A. Costanzo, S. Chimenti (Italy)
- P 102 TREATMENT OF CHRONIC PLAQUE PSORIASIS CRITERIA FOR EFALIZUMAB**
J. Ortonne, P. Beaulieu, P. Niez, E. Leutenegger (France)
- P 103 PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS SHOW IMPROVEMENT IN PATIENT SATISFACTION WITH ETANERCEPT THERAPY: A 12-WEEK INTERIM ANALYSIS**
M. A. de Rie, C. E. M. Griffiths, T. A. Desris, D. Robertson, B. Freundlich, D. J. Chang (The Netherlands)
- P 104 AN EXPERIENCE WITH EFALIZUMAB IN PSORIASIS PATIENTS IN THE MEDICAL CENTER ISSEMYM**
A. Lopeztello, L. I. Juarez (Mexico)
- P 105 URTICARIAN ERUPTION TO ONERCEPT: A CASE REPORT**
H. Chaabene, T. Meziou, S. Marrekchi, H. Ben Salah, H. Turki, A. Zahaf (Tunisia)
- P 106 SEVERE INFLAMMATORY PSORIASIS FLARE DURING EFALIZUMAB THERAPY**
E. Laffitte, O. Gugerli, A. Keta, L. Rothuizen, J. Dudler, R. G. Panizzon (Switzerland)
- P 107 IMMUNOLOGICAL AND CLINICAL EFFECTS OF ALPHACALCIDOL IN PATIENTS WITH PSORIATIC ARTHROPATHY. RESULTS OF AN OPEN, FOLLOW UP PILOTE STUDY**
J. Gaál, G. Lakos, P. Szodoray, M. Alexa, J. Kiss, I. Horváth, E. Horkay, G. Nagy, A. Szegedi (Hungary)
- P 108 OSTEOPENIC SYNDROME IN PATIENTS WITH THE PSORIASIS**
I. A. Oleynik, Y. F. Kutasevych, I. A. Mashtakova, M. I. Spuzyak, M. A. Garkusha (Ukraine)
- P 109 GENERALIZED PUSTULAR PSORIASIS: A NEUTROPHILIC DISEASE?**
S. Benomar, F. Z. Belgnaoui, K. Senouci, B. Hassam (Morocco)

- P 110 PSORIASIS AND ALEXITHYMIA: A CASE-CONTROL STUDY**
H. Ben Salah, A. Masmoudi, S. Marrekchi, H. Chaabène, J. Masmoudi, H. Rached, A. Jaoua, H. Turki (Tunisia)
- P 111 RECOGNIZING PSORIATIC ARTHRITIS IN PSORIASIS PATIENTS: RECOMMENDATION FOR A MULTIDISCIPLINARY APPROACH**
P. Provost, C. Marques da Costa, B. Sessego, J. Bentin, P. Vereecken (Belgium)
- P 112 PSORIASIS AND SEXUAL TROUBLES**
S. Rekik, H. Cheikhrouhou, A. Masmoudi, A. Jaoua, T. Meziou, H. Turki (Tunisia)
- P 113 ON THE HERITABILITY OF PSORIATIC ARTHRITIS**
O. B. Pedersen*, A. J. Svendsen, L. Ejstrup, A. Skytthe, P. Junker (Denmark)
- P 115 THE RELATIVE PSYCHOLOGICAL PROFILE OF PSORIASIS PATIENTS**
G. B. E. Jemec, S. Esmann (Denmark)
- P 116 RISK OF LYMPHOMA IN PSORIASIS: A CASE REPORT**
H. Hammami, K. Jaber, S. Youssef, M. Dhaoui, N. Doss (Tunisia)
- P 118 IMPACT OF OBESITY ON PSORIASIS**
F. Robbana, S. Youssef, F. Ishak, K. Jaber, M. Dhaoui, N. Doss (Tunisia)
- P 122 PSORIASIS VULGARIS AND STRESS**
B. Brankovic Zirojevic, B. Zivkovic (Serbia)
- P 124 PSORIASIS AND HEMATOLOGICAL MALIGNANCIES**
Y. Shapiro, A. D. Cohen, L. Vidavsky, B. Davidovici, E. Hodak, M. David, D. A. Vardy, J. Meyerovitch (Israel)
- P 125 EXPRESSION OF 60KD HEAT SHOCK PROTEIN AND T CELL RECEPTOR IN GUTTATE AND PLAQUE PSORIASIS**
K. Kim, E. Park, C. Kim (South Korea)
- P 126 PSORIASIS VULGARIS IN MONOZYGOTIC TWINS**
A. Szczerkowska Dobosz, K. Niespodziana, E. Kapińska, E. Jasiel Walikowska, M. Lange (Poland)
- P 127 EFFECTS OF CNTO 1275 ADMINISTRATION ON PRIMATE/HUMAN ANTIGEN-RECALL AND HUMORAL IMMUNE RESPONSE FUNCTION**
C. Brodmerkel, Y. Zhu, T. Jiao, G. Treacy, M. A. Mascelli, A. B. Gottlieb (USA)
- P 128 THE DIAGNOSIS OF PSORIASIS VULGARIS BY A IMMUNOFLUORESCENT METHOD**
J. Jautova, H. Zelenkova, J. Baloghova, S. Svicka, E. Simunicova (Slovakia)
- P 129 THE ROLE OF 12/15 LIPOXYGENASE-ISOFORMS IN HUMAN KERATINOCYTE, HACAT**
H. Yoo, T. Kim (South Korea)
- P 130 KAHALALIDE-INDUCED PEMPHIGUS VULGARIS IN A PATIENT WITH CHRONIC PSORIASIS**
H. Sanz, D. R. Garcia, L. V. Calzado, J. P. Rodriguez, R. G. Valverde, F. S. Vanaclocha (Spain)
- P 131 POLYCLONAL IGG CATALYTIC ACTIVITY IN PATIENTS WITH DIFFERENT FORM OF PSORIASIS**
E. Kunder, O. Zykova (Belarus)
- P 132 A NEW PSORIATIC SKIN MODEL FOR DERMOPHARMACEUTICAL APPLICATIONS**
R. Pouliot, J. Jean, G. Bernard, M. Auger, J. Soucy (Canada)
- P 133 CLINICO-HISTOPATHOLOGICAL CORRELATION IN PATIENTS OF PSORIASIS AND PSORIASIFORM DERMATITIS**
A. Singal, S. Mehta, S. N. Bhattacharya, N. Singh (India)
- P 134 OXIDATIVE STRESS IN CIRCULATING BLOOD GRANULOCYTES AS BIOCHEMICAL MARKER OF SEVERE ERYTHRODERMIC AND ARTHROPATHIC FORMS OF PSORIASIS: FEASIBILITY OF ANTIOXIDANTS IN THE COMBINED TREATMENT OF PSORIASIS**
Z. Kharaeva, E. Mikhail'chik, C. De Luca, L. Korkina (Russia)
- P 135 GENE EXPRESSION PROFILE IN PSORIATIC KERATINOCYTES**
S. Pastore, F. Mascia, V. Mariani, L. Rogge, F. Sinigaglia, G. Girolomoni (Italy)
- P 136 CLINICAL EFFICACY OF LOW DOSE INTERFERENTIAL CURRENTS IN THE TREATMENT OF PSORIASIS**
C. De Luca, L. Korkina, J. Reinhold, H. Dertinger (Italy)
- P 137 LLL-3348- A NOVEL BOTANICAL DRUG PRODUCT FOR THE TREATMENT OF STABLE PLAQUE TYPE PSORIASIS**
S. K. Arora, A. Kulasekaran, M. Bijarnia (India)
- P 138 ALOREED OINTMENT (PROPOLIS AND ALOE VERA) AS A NEW MODALITY IN TREATMENT OF PSORIASIS! (AN OVERVIEW OF 3 YEARS EXPERIENCE)**
A. A. S. El-Gammal (Egypt)
- P 139 APITHERAPY AS A NEW APPROACH IN TREATMENT OF PALMOPLANTAR PSORIASIS**
A. A. S. El-Gammal (Egypt)
- P 140 TRACING TOPOPROTEOMICS IN PSORIASIS PATHOGENESIS AND TREATMENT BY MULTI EPTOPE LIGAND CARTOGRAPHY ROBOT TECHNOLOGY (MELC ROBTEC)**
B. Bonnekoh, H. Gollnick (Germany)
- P 141 CLINICAL PECULIARITIES OF NAILS DAMAGED BY SIMULTANEOUSLY PSORIASIS AND ONYCHOMYCOSIS**
T. Leonidze, K. Shvelidze (Georgia)
- P 142 THE BALNEOCLIMATIC TREATMENT OF PATIENTS WITH PSORIASIS AT THE RESORT OF GEORGIA**
T. Leonidze, K. Shvelidze (Georgia)